NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant
Adaptive Trial Skips Monotherapy Arm, Uses Factorial Design
Eli Lilly’s drug is one of many anti-inflammatory medicines in late-stage trials against coronavirus but will be the first to be combined with Gilead’s recently approved remdesivir.
You may also be interested in...
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.
Coronavirus Update: FDA Pulls Hydroxychloroquine Emergency Authorization, Germany Acquires Stake In CureVac
Plus news on the German government's decision to by a 23% stake in mRNA vaccines company CureVac, and Lilly taking Olumiant into Phase III.